source
- Eli Lilly Q2 revenue hits $23 billion, topping forecasts as tirzepatide drives two-thirds of salesEli Lilly reported second-quarter revenue of $23 billion, roughly $3 billion above analysts' estimates. Tirzepatide contributed about 64% of the total, highlighting its central role in the company…
- Lilly and FDA clash over retatrutide classification as company nears submissionEli Lilly is preparing to file its obesity drug candidate retatrutide for approval while a legal dispute with the FDA over the drug's classification intensifies. The agency has concluded that reta…